Literature DB >> 19906919

The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain.

Sandy S Tungteakkhun1, Maria Filippova, Nadja Fodor, Penelope J Duerksen-Hughes.   

Abstract

Human papillomavirus 16 is a causative agent of most cases of cervical cancer and has also been implicated in the development of some head and neck cancers. The early viral E6 gene codes for two alternatively spliced isoforms, E6(large) and E6*. We have previously demonstrated the differential effects of E6(large) and E6* binding on the expression and stability of procaspase 8, a key mediator of the apoptotic pathway. Additionally, we have reported that E6 binds to the FADD death effector domain (DED) at a novel E6 binding domain. Sequence similarities between the FADD and procaspase 8 DEDs suggested a specific region for E6(large)/procaspase 8 binding, which was subsequently confirmed by mutational analysis as well as by the ability of peptides capable of blocking E6/FADD binding to also block E6(large)/caspase 8 binding. However, the binding of the smaller isoform, E6*, to procaspase 8 occurs at a different region, as deletion and point mutations that disrupt E6(large)/caspase 8 DED binding do not disrupt E6*/caspase 8 DED binding. In addition, peptide inhibitors that can block E6(large)/procaspase 8 binding do not affect the binding of E6* to procaspase 8. These results demonstrate that the residues that mediate E6*/procaspase 8 DED binding localize to a different region on the protein and employ a separate binding motif. This provides a molecular explanation for our initial findings that the two E6 isoforms affect procaspase 8 stability in an opposing manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906919      PMCID: PMC2812347          DOI: 10.1128/JVI.01331-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

Review 1.  Tat peptide-mediated cellular delivery: back to basics.

Authors:  Hilary Brooks; Bernard Lebleu; Eric Vivès
Journal:  Adv Drug Deliv Rev       Date:  2005-01-06       Impact factor: 15.470

2.  Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.

Authors:  Yves Nominé; Murielle Masson; Sebastian Charbonnier; Katia Zanier; Tutik Ristriani; François Deryckère; Annie-Paule Sibler; Dominique Desplancq; Robert Andrew Atkinson; Etienne Weiss; Georges Orfanoudakis; Bruno Kieffer; Gilles Travé
Journal:  Mol Cell       Date:  2006-03-03       Impact factor: 17.970

3.  Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis.

Authors:  J Bertin; R C Armstrong; S Ottilie; D A Martin; Y Wang; S Banks; G H Wang; T G Senkevich; E S Alnemri; B Moss; M J Lenardo; K J Tomaselli; J I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 4.  Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease.

Authors:  J S Butel
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

5.  Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines.

Authors:  A Cereseto; Z Berneman; I Koralnik; J Vaughn; G Franchini; M E Klotman
Journal:  Leukemia       Date:  1997-06       Impact factor: 11.528

Review 6.  Human papillomavirus infection: biology, epidemiology, and prevention.

Authors:  M E Scheurer; G Tortolero-Luna; K Adler-Storthz
Journal:  Int J Gynecol Cancer       Date:  2005 Sep-Oct       Impact factor: 3.437

Review 7.  Tumor necrosis factor receptors encoded by poxviruses.

Authors:  K M Cunnion
Journal:  Mol Genet Metab       Date:  1999-08       Impact factor: 4.797

8.  The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP.

Authors:  R C Elston; S Napthine; J Doorbar
Journal:  J Gen Virol       Date:  1998-02       Impact factor: 3.891

9.  The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells.

Authors:  A L Talis; J M Huibregtse; P M Howley
Journal:  J Biol Chem       Date:  1998-03-13       Impact factor: 5.157

10.  Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.

Authors:  Yoko Matsumoto; Shunsuke Nakagawa; Tetsu Yano; Shin Takizawa; Kazunori Nagasaka; Keiichi Nakagawa; Takeo Minaguchi; Osamu Wada; Hajime Ooishi; Koji Matsumoto; Toshiharu Yasugi; Tadahito Kanda; Jon M Huibregtse; Yuji Taketani
Journal:  J Med Virol       Date:  2006-04       Impact factor: 2.327

View more
  19 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.

Authors:  Chung-Hsiang Yuan; Maria Filippova; Sandy S Tungteakkhun; Penelope J Duerksen-Hughes; John L Krstenansky
Journal:  Bioorg Med Chem Lett       Date:  2012-01-10       Impact factor: 2.823

Review 3.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

4.  p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.

Authors:  Thibault Mesplède; David Gagnon; Fanny Bergeron-Labrecque; Ibrahim Azar; Hélène Sénéchal; François Coutlée; Jacques Archambault
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

5.  The small splice variant of HPV16 E6, E6, reduces tumor formation in cervical carcinoma xenografts.

Authors:  Maria Filippova; Whitney Evans; Robert Aragon; Valery Filippov; Vonetta M Williams; Linda Hong; Mark E Reeves; Penelope Duerksen-Hughes
Journal:  Virology       Date:  2014-01-01       Impact factor: 3.616

Review 6.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses.

Authors:  Nicholas A Wallace; Denise A Galloway
Journal:  Semin Cancer Biol       Date:  2014-01-08       Impact factor: 15.707

7.  Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures.

Authors:  Yanxiao Zhang; Lada A Koneva; Shama Virani; Anna E Arthur; Alisha Virani; Pelle B Hall; Charles D Warden; Thomas E Carey; Douglas B Chepeha; Mark E Prince; Jonathan B McHugh; Gregory T Wolf; Laura S Rozek; Maureen A Sartor
Journal:  Clin Cancer Res       Date:  2016-04-18       Impact factor: 12.531

8.  Human papillomavirus type 16 E6* induces oxidative stress and DNA damage.

Authors:  Vonetta M Williams; Maria Filippova; Valery Filippov; Kimberly J Payne; Penelope Duerksen-Hughes
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

Review 9.  PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6.

Authors:  Lennox Chitsike; Penelope J Duerksen-Hughes
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

Review 10.  Molecular Tumor Subtypes of HPV-Positive Head and Neck Cancers: Biological Characteristics and Implications for Clinical Outcomes.

Authors:  Tingting Qin; Shiting Li; Leanne E Henry; Siyu Liu; Maureen A Sartor
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.